滚动资讯
FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targetFierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerFierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapyFierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from AsiaFierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reportsLonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocusLonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.comLonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.comBioWorldJapanese researchers report new μ-opioid receptor antagonistsBioWorldIncyte discloses new TYK2 and/or JAK1 inhibitorsBioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitorsBioWorldNeolaia synthesizes new CD38 inhibitors
PLoS Biology 2025年12月3日

原生生物<i>Paradiplonema papillatum</i>的亚细胞蛋白质组学揭示细胞膜的消化能力及眼虫类生物过氧化物酶体的可塑性

原生生物 Paradiplonema papillatum 的亚细胞蛋白质组学揭示细胞膜的消化能力及眼虫类生物过氧化物酶体的可塑性

原文
暂时没有全文，请查看原始来源。